Background: The incidence of urinary tract calculi is thought to be higher in patients with inflammatory bowel disease (IBD) than that in the general population. However, few data are available about urolithiasis in patients with Crohn's disease (CD). We investigated the incidence of urolithiasis and the risk factors for urolithiasis in patients with CD. Methods: We examined the records of 387 patients with CD followed at Samsung Medical Center from July 2011 to June 2013. Evidence for the presence of calculi was obtained from radiologic findings (plain films, ultrasonography, or computed tomography), urinary colic symptoms, or a treatment history of urolithiasis after diagnosis of CD. Demographic variables, phenotype, concurrent medications, and previous CD-related surgery were analyzed. Results: Urinary tract calculi were found in 18 (4.7%) patients, which developed after the CD diagnosis. The incidence of urolithiasis in CD was 706 per 100,000 patient-years. Cox models with a time-dependent covariate showed that azathioprine (AZA)/6-mercaptopurine (6-MP) treatment (hazard ratio = 0.963; 95% CI: 0.931, 0.996; p = 0.030) was negatively associated with urolithiasis. Conclusions: The annual incidence rate of urolithiasis in patients with CD was 0.7%. AZA/6-MP therapy was associated with a low risk of urolithiasis in these patients.

1.
Manganiotis AN, Banner MP, Malkowicz SB: Urologic complications of Crohn's disease. Surg Clin North Am 2001;81:197-215, x.
2.
Banner MP: Genitourinary complications of inflammatory bowel disease. Radiol Clin North Am 1987;25:199-209.
3.
Van Assche G, Vermeire S, Rutgeerts P: The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol 2010;7:79-85.
4.
Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S: Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
5.
Ye BD, Jang BI, Jeen YT, Lee KM, Kim JS, Yang SK: Diagnostic guideline of Crohn's disease (in Korean). Korean J Gastroenterol 2009;53:161-176.
6.
Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5A-36A.
7.
Lawrance IC, Murray K, Batman B, Gearry RB, Grafton R, Krishnaprasad K, Andrews JM, Prosser R, Bampton PA, Cooke SE, Mahy G, Radford-Smith G, Croft A, Hanigan K: Crohn's disease and smoking: is it ever too late to quit? J Crohns Colitis 2013;7:e665-e671.
8.
Park C, Ha YS, Kim YJ, Yun SJ, Lee SC, Kim WJ: Comparison of metabolic risk factors in urolithiasis patients according to family history. Korean J Urol 2010;51:50-53.
9.
Wang X, Xu X, Wu J, Zhu Y, Lin Y, Zheng X, Xie L: Systematic review and meta-analysis of the effect of alcohol intake on the risk of urolithiasis including dose-response relationship. Urol Int 2014, Epub ahead of print.
10.
Wang S, Zhang Y, Mao Z, He X, Zhang Q, Zhang D: A meta-analysis of coffee intake and risk of urolithiasis. Urol Int 2014;93:220-228.
11.
Ishii G, Nakajima K, Tanaka N, Hara H, Kato M, Ishii N: Clinical evaluation of urolithiasis in Crohn's disease. Int J Urol 2009;16:477-480.
12.
Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT: Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998;93:504-514.
13.
Parks JH, Worcester EM, O'Connor RC, Coe FL: Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003;63:255-265.
14.
Worcester E, Parks JH, Josephson MA, Thisted RA, Coe FL: Causes and consequences of kidney loss in patients with nephrolithiasis. Kidney Int 2003;64:2204-2213.
15.
Jo MK, Kwak C, Park SK, Yoo KY, Kang DH, Kim HH, Lee CW, Kim SH: Prevalence and epidemiological characteristics of urolithiasis for adults aged 40-79 in Seoul, Korea. Korean J Urol 2000;41:367-374.
16.
Primas C, Novacek G, Schweiger K, Mayer A, Eser A, Papay P, Gratzer C, Angelberger S, Dejaco C, Reinisch W, Vogelsang H: Renal insufficiency in IBD - prevalence and possible pathogenetic aspects. J Crohns Colitis 2013;7:e630-e634.
17.
Knudsen L, Marcussen H, Fleckenstein P, Pedersen EB, Jarnum S: Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol 1978;13:433-436.
18.
Worcester EM: Stones from bowel disease. Endocrinol Metab Clin North Am 2002;31:979-999.
19.
Cury DB, Moss AC, Schor N: Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis 2013;6:139-142.
20.
Mukewar S, Hall P, Lashner BA, Lopez R, Kiran RP, Shen B: Risk factors for nephrolithiasis in patients with ileal pouches. J Crohns Colitis 2013;7:70-78.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.